Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13818150 | 0.86 | TAAR1 (0.47) | TAAR1GRM4CTSBCTSSCTSK | |
| SCHEMBL17970596 | 0.81 | TAAR1 (0.42) | TAAR1GRM4CTSBCTSSCTSK | |
| SCHEMBL18588463 | 0.81 | TAAR1 (0.42) | TAAR1GRM4CTSBCTSSCTSK | |
| SCHEMBL21716647 | 0.81 | L3MBTL1 (0.45) | TAAR1GRM4CTSBCTSSCTSK | |
| SCHEMBL4824953 | 0.80 | GRM4 (0.44) | TAAR1GRM4CTSBCTSSCTSK | |
| SCHEMBL14159195 | 0.80 | TAAR1 (0.58) | TAAR1HSD17B10ALDH1A1CASP1MC4R | |
| SCHEMBL4598374 | 0.80 | GRM4 (0.44) | TAAR1GRM4CTSBCTSSCTSK | |
| SCHEMBL24904183 | 0.79 | LMNA (0.42) | TAAR1GRM4CTSBCTSSCTSK | |
| SCHEMBL22415478 | 0.79 | KMT2A (0.54) | TAAR1GRM4CTSBCTSSCTSK | |
| SCHEMBL21347705 | 0.79 | SIGMAR1 (0.47) | CTSBCTSSCTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| US-11357828-B2 | Releasable GLP-1 conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2022-06-14 | — | — | US | disclosed |
| US-20220118055-A1 | RELEASABLE GLP-1 CONJUGATES | FISH & RICHARDSON PC | 2022-04-21 | — | — | US | disclosed |
| US-20210170045-A1 | RELEASABLE ANTIBODY CONJUGATES | FISH & RICHARDSON PC | 2021-06-10 | — | — | US | disclosed |
| WO-2020053815-A1 | RELEASABLE GLP-1 CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170045-A1 | RELEASABLE ANTIBODY CONJUGATES | BCR, CD47, RNASE1 | TAAR1 4785/4885GRM4 4777/4885CTSB 252/4885 |
| US-11357828-B2 | Releasable GLP-1 conjugates | GLP1R, GIPR, IAPP | TAAR1 2682/4885GRM4 2623/4885CTSB 1315/4885 |
| US-20220118055-A1 | RELEASABLE GLP-1 CONJUGATES | GLP1R, GIPR, IAPP | TAAR1 2682/4885GRM4 2623/4885CTSB 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.